COVID-19 infection is caused by the novel severe acute respiratory syndrome coronavirus 2
(SAR-CoV-2). This novel virus has transformed into different resistant variants (eg, omicron; …

Objective Randomized controlled trials comparing tocilizumab and baricitinib in patients with
coronavirus disease 2019 (COVID-19) are needed. This was an open-label, randomized …

Background: To date, minimal data directly compare tocilizumab with baricitinib for treatment
in moderate to severe COVID-19. Objective: To compare the rates of in-hospital mortality …

Background: Baricitinib is a Janus kinase (JAK) inhibitor with a broader anti-inflammatory
activity than tocilizumab and an antiviral potential although no head-to-head trials are …

Objectives The immunomodulators tocilizumab and baricitinib improve outcomes in severely
ill patients with coronavirus disease 2019 (COVID‐19); however, comparative analyses of …

Background Tocilizumab and baricitinib are immunomodulators that have been repurposed
for the treatment of coronavirus disease 2019 (COVID-19). Whether one medication should …

Objectives: The National Institutes of Health and Infectious Diseases Society of America
guidelines recommend tocilizumab or baricitinib in the management of severe COVID-19 …

Objective: This review was performed to compare the efficacy and safety among hospitalized
patients with COVID-19 who received baricitinib and those who received tocilizumab …

Introduction: Tocilizumab and baricitinib are recommended treatment options for COVID-19
patients with hyperinflammatory response; however, there is a lack of systematic review …

Background and Objectives: Tocilizumab and baricitinib have been observed to improve the
outcomes of patients with coronavirus disease 2019 (COVID-19). However, a comparative …